Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Learn about new and existing offerings from NovoCare®
NovoCare® is our access and affordability resource for patients, with helpful info on new and existing options.
Find out more at NovoCare.com
Human insulin is used by millions of Americans for the treatment of both type 1 and type 2 diabetes, and is a safe and effective option when used under the supervision of a healthcare professional.
Clayton & Durham, NC
West Lebanon, NH
shouldn’t stop us from going for gold January 13, 2020
all Press Releases
All personal information reported in relation to a complaint or a
side effect will be processed in accordance with applicable data
protection legislation. For avoidance of doubt, “data protection
legislation” means the law governing the Novo Nordisk entity receiving
the complaint or report, not the residence or location of the
individual data subject submitting the report or complaint: